Assay development

BiomarkerBay unique capabilities

  • Collaboration with state of the art LC-MS/MS facilities for proteomic and metabolomic analyses

  • Development of large molecule immunobioanalysis

  • Development of intracellular and cell specific flowcytometry assays


The second step in the biomarker research workflow is the development of specific assays for the analysis of the successfully identified biomarkers. The specifications of the assay characteristics, as the type of biomarker, the matrix and the technique(s) used for detection,  have to be carefully selected to fit with its intended use, in accordance with the customer and regulatory requirements.


The BiomarkerBay partners have broad experience in assay development and offer high quality expertise and high flexibility in working with a large variety of samples and technologies, in  research, patient care or CRO settings.  Our list includes:

  • labType of biomarker: small molecules, proteins, peptides, oligonucleotides, cDNA, miRNA, metal and non metal elements;
  • Type of matrices: whole blood, plasma, serum, urine, faeces, cells, tissues, cerebral spinal fluids, DNA and RNA;
  • Methodology: ELISA, LC-MS/MS, qPCR, flow cytometry, multiplexing, antibody production, liquid chromatography, whole proteome-MS.

For an overview of established assays, please check our assay database.


Take away message: BiomarkerBay in a nutshell - download our flyer here.